<DOC>
	<DOCNO>NCT02829723</DOCNO>
	<brief_summary>The purpose first-in-human ( FIH ) study BLZ945 give single agent combination PDR001 characterize safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics , anti-tumor activity BLZ945 , administer orally , single agent combination PDR001 , administer intravenously ( i.v . ) adult patient advance solid tumor . Dose escalation guide Bayesian logistic regression model overdose control . Once MTD/ RP2D declare , patient enrol phase II part select indication ( glioblastoma , pancreatic cancer triple negative breast cancer ) ass preliminary anti-tumor activity BLZ945 combination PDR001 . Should sign anti-tumor activity see phase I dose escalation BLZ945 single agent , phase II part open order explore BLZ945 single agent efficacy recommend dose .</brief_summary>
	<brief_title>Phase I/II Study BLZ945 Single Agent BLZ945 Combination With PDR001 Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Phase I : Patients advanced/metastatic solid tumor , measurable unmeasurable disease determine Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 2 . Phase I : Patients site disease amenable biopsy , willing undergo new tumor biopsy screening , treatment . 3 . Phase II : Patients advanced/metastatic tumor select indication , least one measurable lesion determine RECIST v1.1 RANO advance pancreatic cancer advance triple negative breast cancer , recurrent glioblastoma Other protocol define inclusion criterion may apply 1 . History severe hypersensitivity reaction monoclonal antibody . 2 . Impaired cardiac function clinically significant cardiac disease . 3 . Active autoimmune disease document history autoimmune disease . 4 . Systemic steroid therapy immunosuppressive therapy 5 . Use vaccine infectious disease within 4 week initiation study treatment . 6 . Patient receive treatment medication either strong inducer inhibitor CYP2C8 CYP3A4/5 , patient receive medication prohibits proton pump inhibitor discontinue least 1 week prior start treatment duration study . Other protocol define exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase I/II</keyword>
	<keyword>BLZ945</keyword>
	<keyword>PDR001</keyword>
	<keyword>CSF-1R</keyword>
	<keyword>PD-1</keyword>
</DOC>